Aqueous liquid composition
AssigneeSumitomo Dainippon Pharma Co., Ltd.
InventorsTomomi NAKATANI, Koichi SAITO
Life of this patent
Estimating the term…
Loading patent…
AssigneeSumitomo Dainippon Pharma Co., Ltd.
InventorsTomomi NAKATANI, Koichi SAITO
Estimating the term…
The invention provides an aqueous liquid composition comprising a WT1 protein-derived cancer antigen peptide, wherein the peptide is stabilized. The aqueous liquid composition contains a peptide and an excipient, and has a pH of 3-6. The peptide has the amino acid sequence Arg-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu (SEQ ID NO: 1), wherein optionally 1 to 3 amino acids are deleted, substituted and/or added, such that the peptide has a cytotoxic T cell-inducing ability. The excipient is (a) an alpha hydroxyl acid selected from glycolic acid, lactic acid, malic acid, tartaric acid, citric acid and pharmacologically acceptable salts thereof, (b) a dicarboxylic acid selected from malonic acid, succinic acid, glutaric acid, maleic acid and pharmacologically acceptable salts thereof, and/or (c) methionine.
An aqueous liquid composition comprising the peptide and the excipient, and having a pH of 3-6:
A method of improving stability of a peptide, consisting of the amino acid sequence shown by Arg-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu (SEQ ID NO:
Dependencies are inferred from the claim text.